News and Events

Switching from Saxenda (liraglutide, daily) to Wegovy (semaglutide, weekly) is common for patients seeking greater weight loss or fewer injections. Based on the official US labels and published guidance, this guide explains why patients switch, compares the dosing schedules, and outlines the transition step by step: no washout is needed, Wegovy can usually start the day after the last Saxenda dose, the starting dose is typically 0.25 mg (0.5 mg considered off-label for some patients stable on 3 mg), and escalation occurs every 4 weeks. It also covers expected GI side effects, STEP 8 trial results, common mistakes and what the GLP-1 trend means for aesthetic clinics and distributors.

Tranexamic acid (TXA) mesotherapy has become a go-to option for clinics treating stubborn melasma. This guide explains how TXA interrupts the plasmin signal that drives pigment production, what published clinical studies show (Lee 2006; Budamakuntla 2013), how a typical intradermal TXA protocol is run, which brightening actives it pairs well with, key safety considerations, and a sourcing checklist for distributors and clinic brands looking to import or private-label a TXA formula.

Hair loss is one of the most emotionally significant aesthetic concerns a patient can present with — and one of the most under-treated in clinic settings, largely because the available solutions have historically been limited to topicals (minoxidil, finasteride), invasive surgery, or waiting. Mesoth

Skin brightening injections are often marketed for uneven tone and hyperpigmentation. This guide explains what glutathione may do, how supporting ingredients are used, what evidence can and cannot show, and the safety questions clinics and patients should discuss.